The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Proteome Characterization Centers for Clinical Proteomic Tumor Analysis Consortium (U24)
This Funding Opportunity Announcement (FOA) is a part of the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC). This reissuance of the CPTAC program leverages recent advancements in cancer proteomics and genomics and accelerates research in these areas by disseminating research resources for the scientific community. The program will support broad efforts focused on several cancer types to explore further the complexities of cancer proteomes and their connections to abnormalities in cancer genomes. The potential of proteomic and proteo-genomic approaches will also be explored in translational research focused on clinically-relevant problems.
This FOA solicits applications for multidisciplinary Proteome Characterization Centers (PCCs). PCC awardees will be expected to work as an interactive group and use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically-characterized samples. These samples (human biospecimens, cultured cells, and animal cancer models) will be provided by the NCI.
PCCs will interact with additional CPTAC sub-programs that include:
- Proteogenomic Data Analysis Centers (PGDAC, to be supported by RFA-CA-15-023) that will conduct integrative analyses of data across the entire proteomes and genomes of cancer types of focus to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level; and
- Proteogenomic Translational Research Centers (PTRCs, to be supported under RFA-CA-15-022) that will apply state-of-the-art proteomic and proteo-genomic approaches to elucidate responses to cancer therapeutic agents, e.g., in order to predict which therapeutic agents are likely to be effective against a specific patient's tumor.
- Letter of Intent Due Date(s): 30 days prior to application due date
- Application Due Date(s): January 27, 2016, by 5:00 PM local time of applicant organization.
RFA-CA-15-021 Expiration Date January 28, 2016
An individual designated as PD/PI on a PGDAC application in response to RFA-15-023 cannot be designated as a PD/PI under this FOA. However, these individuals can serve as key persons within a PCC application.
Application budgets for each Center may not exceed $800,000 in direct costs per year and need to reflect the actual needs of the proposed project.
Applicants may request up to 5 years of support.